MarketMoodz
Amgen Seeks FDA Hearing to Fight Tavneos Withdrawal
Amgen and its ChemoCentryx unit asked the FDA for a formal hearing to challenge the agency’s proposed withdrawal of Tavneos (avacopan), its treatment for ANCA-associated vasculitis. The request triggers a June 29, 2026 deadline for Amgen to submit detailed data and opens a process that could preserve or end the drug’s commercial life.
Key Takeaways
- Amgen and ChemoCentryx formally requested an FDA hearing to contest the proposed withdrawal of Tavneos (avacopan).
- FDA CDER issued a Notice of Opportunity for a Hearing on April 30, 2026, and set a June 29, 2026 deadline for Amgen’s submission of supporting data.
- Amgen argues Tavneos’ benefits outweigh its risks and plans to submit detailed data, analyses, and supporting information by the June 29 deadline.
- Duke Clinical Research Institute began an independent review of pivotal trial data in February, a review cited in Amgen’s June 1 filing.
- Market reaction was muted: AMGN was down roughly 0.05% to $357.32 at the time of reporting.
People Involved
- No specific individuals mentioned
Entities Involved
- Amgen Inc. (AMGN)Biotech company seeking a hearing to contest FDA's proposed withdrawal of Tavneos
- ChemoCentryx, Inc.Amgen subsidiary and original developer of Tavneos involved in the filing
- U.S. Food and Drug Administration - CDERRegulatory body that issued the Notice of Opportunity for a Hearing on Tavneos
- Duke Clinical Research InstituteConducting an independent review of Tavneos’ pivotal trial data cited by Amgen
MarketMoodz Analysis
For investors, the hearing request turns a regulatory action into a near-term binary risk with measurable financial stakes. If the FDA proceeds with withdrawal, Amgen would lose Tavneos’ revenue stream and face reputational and pipeline-confidence headwinds; if the hearing halts or reverses the withdrawal, the company preserves an approved therapy and limits downside to sales and guidance. The reported June 29 submission deadline creates a clear milestone: analysts will judge not only the outcome but the quality and completeness of the data Amgen files, and that assessment will drive short-term sentiment and potential re-rating.
The involvement of the Duke Clinical Research Institute adds a layer of independent scrutiny that investors will parse closely. Regulators have reversed or modified approvals in past biotech cases after new analyses—sometimes restoring access, sometimes cementing withdrawal—so outcome uncertainty remains high. Given that Tavneos treats a rare disease, commercial volumes are limited relative to Amgen’s blockbuster drugs, but rare-disease therapies can carry outsized valuation impact through pricing, margins, and pipeline credibility; the market’s muted move so far (AMGN down ~0.05% to $357.32) suggests investors are waiting for the June 29 submission and any formal hearing schedule.
What to watch next: the June 29 filing itself and whether it contains new patient-level data or re-analyses from the Duke review; the FDA’s timetable for a hearing and whether patients, caregivers, or independent experts will be allowed to testify; and near-term commentary from Amgen’s management and sell-side analysts on revenue exposure and modeling changes. Each development will recalibrate the odds of withdrawal versus preservation and determine whether this becomes an operational hiccup or a material hit to Amgen’s portfolio.
Source: Original Article